

DAFTAR PUSTAKA

1. Ma J, Coa S. The Epidemiology of Nasopharyngeal Carcinoma. In: Nasopharyngeal Cancer Multidisciplinary Management. Berlin: Springer; 2010. 1–8.
2. Brennan B. Nasopharyngeal carcinoma. *Orphanet J Rare Dis.* 2006;1(1):1–5.
3. Wei william ignace, Chua daniel T. Nasopharyngeal Carcinoma. In: Johnson J, Rosen C, editors. *Bailey's Head & Neck Surgery Otolaryngology.* Philadelphia: Lippincott Williams & Wilkins; 2014.1875–97.
4. Rahman S, Budiman BJ, Subroto H. Faktor Risiko Non Viral pada Karsinoma Nasofaring. *J Kesehat Andalas.* 2015;4(3):988–95.
5. Adham M, Kurniawan A, Muhtadi A, Roezin A, Hermani B, Gondhowiardjo S, et al. Nasopharyngeal carcinoma in Indonesia : epidemiology, incidence, sign and symptoms at presentation. *Chin J Cancer.* 2014;185–96.
6. Melani W, Sofyan F. Karakteristik Penderita Kanker Nasofaring di Rumah Sakit H . Adam Malik Medan Tahun 2011. *E-Jurnal FK-USU.* 2013;1(1):1–5.
7. Mahdavifar N, Ghoncheh M, Mohammadian A, Khosravi Ba, Salehiniya H. Epidemiology and inequality in the incidence and mortality of nasopharynx cancer in Asia. *Osong Public Heal Res Perspect.* 2016;7(6):360–72.
8. Yenita AA. Penelitian Korelasi antara Latent Membrane Protein-1 Virus Epstein-Barr dengan P53 pada Karsinoma Nasofaring (Penelitian Lanjutan). *J Kesehat Andalas.* 2012;1(1):4–6.
9. Faiza S, Rahman S, Asri A. Karakteristik Klinis dan Patologis Karsinoma Nasofaring di Bagian THT-KL RSUP Dr.M.Djamil Padang. *J Kesehat Andalas.* 2016;5(1):90–6.
10. Ekburanawat W, Ekpanyaskul C, Brennan P, Kanka C, Tepsuwan K, Temiyastith S, et al. Evaluation of non-viral risk factors for nasopharyngeal carcinoma in Thailand: Results from a case-control study. *Asian Pacific J Cancer Prev.* 2010;11:929–32.
11. Bruce JP, Yip K, Bratman S V., Ito E, Liu FF. Nasopharyngeal cancer: Molecular landscape. *J Clin Oncol.* 2015;33(29):3346–55.
12. Han B-L, Xu X-Y, Zhang C-Z, Wu J-J, Han C-F, Wang H, et al. Systematic Review on Epstein-Barr Virus (EBV) DNA in Diagnosis of Nasopharyngeal Carcinoma in Asian Populations. *Asian Pacific J Cancer Prev.* 2012;13(6):2577–81.

13. Tsang CM, Tsao SW. The role of Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. *Virology*. 2015;30(2):107–21.
14. Karanikiotis C, Daniilidis M, Karyotis N, Bakogiannis C, Economopoulos T, Murray S, et al. HLA class II alleles and the presence of circulating Epstein-Barr virus DNA in Greek patients with nasopharyngeal carcinoma. *Strahlentherapie und Onkol*. 2008;184(6):325–31.
15. Su W, Hildesheim A, Chang Y. Human leukocyte antigens and Epstein – Barr virus-associated nasopharyngeal carcinoma : old associations offer new clues into the role of immunity in infection-associated cancers. *Cancer Epidemiol Prev*. 2013;3(December):1–9.
16. Lu CC, Chen JC, Jin YT, Yang HB, Chan SH, Tsai ST. Genetic susceptibility to nasopharyngeal carcinoma within the HLA-A locus in Taiwanese. *Int J Cancer*. 2003;103(6):745–51.
17. Li X, Fasano R, Wang E, Yao K-T, Marincola FM. HLA Association with Nasopharyngeal Carcinoma. *Curr Mol Med*. 2009;9(6):751–65.
18. Geng XT, Hu YH, Dong T, Wang RZ. Associations of human leukocyte antigen-DRB1 alleles with nasopharyngeal carcinoma and its clinical significance in Xinjiang Uyghur Autonomous Region of China. *Chin Med J (Engl)*. 2016;129(11):1347–54.
19. Li M, Cheung AKL, Yee Ko JM, Lung HL, Cheng Y, Dai W. The interplay of host genetic factors and Epstein-Barr virus in the development of nasopharyngeal carcinoma. *Chin J Cancer*. 2014;33(11):566–8.
20. Yu KJ, Gao X, Chen C, Yang XR, Diehl SR, Goldstein A, et al. Association of Human Leukocyte Antigens (HLA) with Nasopharyngeal Carcinoma (NPC) in High Risk Multiplex Families in Taiwan. *Hum Immunol*. 2009;70(11):910–4.
21. Burt D, Vaughan L, Davis S, Smith G, Nisperos B, Swanson GM. Associations between Human Leukocyte Antigen Type and Nasopharyngeal Carcinoma in Caucasians in the United States. *Cancer Epidemiol Biomarkers Prev*. 1996;5(November):879–87.
22. Judajana R. Asosiasi Human Leukocyte Antigen (HLA) Karsinoma Nasofaring (KNF). *Indones J Clin Pathol Med Lab*. 2009;15(2):52–6.
23. Savitri E, Kuhuwael FG, Punagi AQ, Agus IG. HIA-a24 Gen Allele At Peripheral Blood Samples And Nasopharyngeal Cytobrush In Nasopharyngeal Carcinoma Patients In Makassar. *int Biol Med Res*. 2014;5(3):4350–4.
24. Salehiniya H, Mohammadian M, Mahdavifar N. Nasopharyngeal cancer in the

- world: Epidemiology, incidence, mortality and risk factors. *World Cancer Res J.* 2018;5(1):1–8.
25. Ianovski I, Izzard M, Morton RP, Plank LD. Nasopharyngeal carcinoma : differences in presentation between different ethnicities in the New Zealand setting. *ANZ J Surg.* 2010;80:254–7.
 26. Astang A. Karakteristik Penderita Karsinoma Nasofaring pada Pasien Rawat jalan di Rumah Sakit Umum Pusat Dr. Wahidin Sudirohusodo Periode Juni 2016- Juni 2017. Fakultas Kedokteran Universitas Hasanuddin; 2017.
 27. Ondrey FG, Wright S. Neoplasms of The Nasopharynx. In: Snow J, Ballenger J, editors. *Ballenger’s Otorhinolaryngology Head and Neck Surgery.* Sixteenth. Ontario: BC Decker Inc; 2003. 1392–407.
 28. Sudiono J, Hassan I. DNA Epstein-Barr virus (EBV) sebagai biomaker diagnosis karsinoma nasofaring. *Dent J (Maj Ked Gigi).* 2013;46(3):140–7.
 29. Liu Y, Du C, Lin C, Chan C, Chen C, Wang J. Increased morbidity from nasopharyngeal carcinoma and chronic pharyngitis or sinusitis among workers at a newspaper printing company. *Epidemiol Rev.* 2002;59:18–22.
 30. Tao Q, Chan ATC. Nasopharyngeal carcinoma: Molecular pathogenesis and therapeutic developments. *Expert Rev Mol Med.* 2007;9(12):1–24.
 31. Chani FY. Hubungan Antara Faktor Risiko dengan Kejadian Karsinoma Nasofaring di RSUD Dr.H.Abdul Moeloek Provinsi Lampung Periode Tahun 2015-2017. 2018.
 32. Tabuchi K, Nakayama M, Nishimura B, Hayashi K, Hara A. Early Detection of Nasopharyngeal Carcinoma. *Int J Otolaryngol.* 2011;1–6.
 33. Guo X, Johnson R, Deng H, Liao J, Nelson G, Tang M, et al. Evaluation of non-viral risk factors for nasopharyngeal carcinoma in a high-risk population of Southern China. *Int J cancer.* 2015;142(5):669–71.
 34. Savitri E, Fadjar M, Sriwardani H. HLA-A01 Gene in Nasopharyngeal Carcinoma Patients and Controls in Makassar. *Int J Sci Basic Appl Res.* 2015;18(2):318–26.
 35. Roy Chattopadhyay N, Das P, Chatterjee K, Choudhuri T. Higher incidence of nasopharyngeal carcinoma in some regions in the world confers for interplay between genetic factors and external stimuli. *Drug Discov Ther.* 2017;11(4):170–80.
 36. Zeng M, Zeng Y. Pathogenesis and Etiology of Nasopharyngeal Carcinoma. In: Brady L, Heilmann H, Molls M, Nieder B, editors. *Nasopharyngeal CAnCer Multidisciplinary Management.* New York: Springer New York LLC; 2010. 9–26.

37. Hassen E, Nahla G, Bouaouina N, Chouchane L. The human leukocyte antigen class i genes in nasopharyngeal carcinoma risk. *Mol Biol Rep.* 2010;37(1):119–26.
38. Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. *Cancer Epidemiol Biomarkers Prev.* 2006;15(10):1765–77.
39. Jia WH, Luo XY, Feng BJ, Ruan HL, Bei JX, Liu WS, et al. Traditional Cantonese diet and nasopharyngeal carcinoma risk: A large-scale case-control study in Guangdong, China. *BMC Cancer.* 2010;10:1–7.
40. Turkoz FP, Celenkoglu G, Dogu GG, Kalender ME, Coskun U, Alkis N, et al. Risk factors of nasopharyngeal carcinoma in Turkey-an epidemiological survey of the Anatolian Society of Medical Oncology. *Asian Pac J Cancer Prev.* 2011;12(11):3017–21.
41. Armstrong RW, Imrey PB, Lye MS, Armstrong MJ, Yu MC, Sani S. Nasopharyngeal carcinoma in Malaysian Chinese: Occupational exposures to particles, formaldehyde and heat. *Int J Epidemiol.* 2000;29(6):991–8.
42. Bosetti C, McLaughlin JK, Tarone RE, Pira E, La Vecchia C. Formaldehyde and cancer risk: A quantitative review of cohort studies through 2006. *Ann Oncol.* 2008;19(1):29–43.
43. Hauptmann M, Lubin JH, Stewart PA, Hayes RB, Blair A. Mortality from solid cancers among workers in formaldehyde industries. *Am J Epidemiol.* 2004;159(12):1117–30.
44. Hsu WL, Chen JY, Chien YC, Liu MY, You SL, Hsu MM, et al. Independent effect of EBV and cigarette smoking on nasopharyngeal carcinoma: A 20-year follow-up study on 9,622 males without family history in Taiwan. *Cancer Epidemiol Biomarkers Prev.* 2009;18(4):1218–26.
45. Subroto H, Rahman S, Budiman B, Asri A. Ekspresi epidermal growth factor receptor pada karsinoma nasofaring subtipe tidak berkeratin di RSUP Dr. M. Djamil Padang. Andalas University; 2015.
46. Lo simon S, Lu JJ. Natural history, Presenting Symptoms and Diagnosis of Nasopharyngeal Carcinoma. In: Brady L, Heilmann H, Molls M, Nieder B, editors. *Nasopharyngeal Cancer Multidisciplinary Management.* New York: Springer New York LLC; 2010. 41–52.
47. Wei WI, Kwong DLW. Current Management Strategy of Nasopharyngeal Carcinoma. *Clin Exp Otorhinolaryngol.* 2010;3(1):1.
48. Lee A, Lydiatt W, Colevas D, Glastonbury C, Le QT, Sullivan BO. Nasopharyng.

- In: AJCC Cancer Staging Manual. Eight. Chicago: Springer; 2017. p. 103–11.
49. Bray F, Haugen M, Moger TA, Tretli S, Aalen OO, Grotmol T. Age-incidence curves of nasopharyngeal carcinoma worldwide: Bimodality in low-risk populations and aetiologic implications. *Cancer Epidemiol Biomarkers Prev.* 2008;17(9):2356–65.
 50. Rahman S, Novianti D. Clinical presentation of nasopharyngeal carcinoma in West Sumatera Indonesia. *Med J Malaysia.* 2005;60(5):624–8.
 51. Chua M, Wee J, Hui E, Chan A. Nasopharyngeal Carcinoma. *Lancet.* 2016;387(10022):1012–24.
 52. Mosaad YM. Clinical Role of Human Leukocyte Antigen in Health and Disease. *Scand J Immunol.* 2015;82:283–306.
 53. Ayna T, Kocytgit A. Detection of Anti-HLA Antibodies by Flow Cytometer. In: *Flow Cytometry.* Licensee InTech; 2016. 131–53.
 54. Munir D. Peran HLA pada Karsinoma Nasofaring. *Maj Kedokt Nusant.* 2006;39(3):324–30.
 55. Murphy NM, Burton M, Powell DR, Rossello FJ, Cooper D, Chopra A, et al. Haplotyping the human leukocyte antigen system from single chromosomes. *Sci Rep.* 2016;(June):1–9.
 56. Lazaro A, Tu B, Yang R, Xiao Y, Kariyawasam K, Ng J, et al. Human Leukocyte Antigen (HLA) Typing by DNA Sequencing. In: *Transplantation Immunology: Methods and Protocols.* Springer Science + Business Media; 2013. 1–10.
 57. Caron E, Kowalewski DJ, Koh CC, Sturm T, Schuster H, Aebersold R. Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry *. *Am Soc Biochem Mol Biol.* 2015;3105–17.
 58. Afridi S, Hoessli DC, Waqar M. Mechanistic understanding and significance of small peptides interaction with MHC class II molecules for therapeutic applications. *Immunol Rev.* 2016;272:151–68.
 59. Bratawijaya K, Rengganis I. Kompleks Histocompatibilitas Mayor. In: *Imunologi Dasar.* 2010.197–216.
 60. Fisette O, Wingbermuehle S, Tampé R, Schäfer L V. Molecular mechanism of peptide editing in the tapasin – MHC I complex. *Sci Rep.* 2016;(January):1–13.
 61. Kobayashi KS, Van Den Elsen PJ. NLRC5: A key regulator of MHC class I-dependent immune responses. *Nat Rev Immunol.* 2012;12(12):813–20.
 62. Chan SH, Chew CT, Prasad U, Wee GB, Srinivasan N, Kunaratnam N. HLA and nasopharyngeal carcinoma in Malays. *Br J Cancer.* 1985;51:389–92.

63. Hildesheim A, Apple RJ, Chen CJ, Wang SS, Cheng YJ, Klitz W, et al. Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. *J Natl Cancer Inst.* 2002;94(23):1780–9.
64. Hu SP, Day NE, Luben RN, Cai KL, Li B, Lu XZ, et al. Further evidence for an HLA-related recessive mutation in nasopharyngeal carcinoma among the Chinese. *Br J Cancer.* 2005;92:967–70.
65. Baizig NM, Ayed K, Ayed F Ben, Ayed S, Sassi F, Ladgham A, et al. Association between HLA-A/-B antigens and -DRB1 alleles and nasopharyngeal carcinoma in Tunisia. *Oncology.* 2001;61(1):55–8.
66. Dardari RD, Hyatti MK, Ouhadi HJ, Enider AB, Ttayebi HE, Ahlain AK. Study of Human Leukocyte Antigen Class I Phenotypes in Moroccan Patients With Nasopharyngeal Carcinoma. *Int J Cancer.* 2001;92:294–7.
67. Junior D, Palomares NB, Normando D, Cardoso C. Race versus ethnicity: Differing for better application. *Dent Press J Orthod.* 2010;15(3):121–4.
68. Setiawan A. Klasifikasi Ras Manusia. *Geograph*88. 2016. p. 1–2.
69. Naim A, Syaputra H. Kewarganegaraan, Suku Bangsa, Agama dan Bahasa Sehari-hari Penduduk Indonesia. Jakarta: Badan Pusat Statistik; 2011. 8-10.
70. Olson S. Mapping Human History : Gen, Ras dan Asal Usul Manusia. 2002.
71. Sastroasmoro S, Ismael S. Dasar-dasar metodologi penelitian klinis. 2nd ed. Jakarta: Sagung Seto; 2002. 259-287.
72. Safavi A, Raad N, Raad N, Ghorbani J. Epidemiology of nasopharyngeal cancers in Iran: A 6-year report. *Asian Pacific J Cancer Prev.* 2015;16(10):4447–50.
73. S K. Epidemiological and etiological factors associated with nasopharyngeal carcinoma. *IMCR Bull.* 2003;33(9).
74. Lee LK, Tan EL, Gopala K, Sam CK. Human leukocyte class I antigen alleles A2 and A11 are not associated with nasopharyngeal carcinoma in West Malaysia. *Singapore Med.* 2007;48(7):632–4.
75. Li X, Ghandri N, Piancatelli D, Adams S, Chen D, Robbins FM, et al. Associations between HLA Class I alleles and the prevalence of nasopharyngeal carcinoma (NPC) among Tunisians. *J Transl Med.* 2007;5:1–13.
76. Wang R, Hu Y, Yindom LM, Huang L, Wu R, Wang D, et al. Association analysis between HLA-A, -B, -C, -DRB1, and -DQB1 with nasopharyngeal carcinoma among a Han population in Northwestern China. *Hum Immunol.* 2014;75(3):197–202.